Complications of Intravitreal Injections in Patients with Diabetes

References

• Peyman GA, Lad EM, Moshfeghi DM. Intravitreal injection of therapeutic agents. Retina 2009;29(7):875–912
   PubMed Web of Science ®Google Scholar
• Johnson MW. Etiology and treatment of macular edema. Am J Ophthalmol 2009;147(1):11–21 e1
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91(12):1464–74
   PubMed Web of Science ®Google Scholar
• Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118(4):609–14
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117(6):1064–1077 e35
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 2012;119(11):2312–8
   PubMed Web of Science ®Google Scholar
• Ramulu PY, Do DV, Corcoran KJ, et al. Use of retinal procedures in medicare beneficiaries from 1997 to 2007. Arch Ophthalmol 2010;128(10):1335–40
   PubMedGoogle Scholar
• Williams GA, The office of the inspector general and you. New Retina MD 2013. Available from: http://bmctoday.net/newretinadoc/2013/04/article.asp?f=the-office-of-the-inspector-general-and-you [last accessed 2014]
   Google Scholar
• Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248(7):915–30
   PubMed Web of Science ®Google Scholar
• Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocrinol Metab 2012;16(Suppl 1):S27–36
   PubMedGoogle Scholar
• Fong DS, Aiello LP, Gardner TW, et al. Diabetic retinopathy. Diabetes Care 2004;27(10):2540–53
   PubMed Web of Science ®Google Scholar
• Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators. Am J Med 2007;120(9 Suppl 2):S12–7
   PubMed Web of Science ®Google Scholar
• Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30(1):162–72
   PubMed Web of Science ®Google Scholar
• Lehto S, Rönnemaa T, Pyörälä K, et al. Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes. Stroke 1996;27(1):63–8
   PubMed Web of Science ®Google Scholar
• Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287(19):2570–81
   PubMed Web of Science ®Google Scholar
• Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009;43(3):490–501
   PubMed Web of Science ®Google Scholar
• Hayman SR, Leung N, Grande JP et al. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep 2012;14(4):285–94
   PubMed Web of Science ®Google Scholar
• Gallagher KA, Liu ZJ, Xiao M, et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 2007;117(5):1249–59
   PubMed Web of Science ®Google Scholar
• Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg 2009;62(6):707–9
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 2009;27(20):3385–90
   PubMed Web of Science ®Google Scholar
• Christoforidis JB, Wang J, Jiang A, et al. The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing. Clin Ophthalmol 2013;7:185–91
   PubMedGoogle Scholar
• Christoforidis J, Ricketts R, Pratt C, et al. The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model. Clin Ophthalmol 2012;6:61–9
   PubMedGoogle Scholar
• Breuing K, Eriksson E, Liu P, et al. Healing of partial thickness porcine skin wounds in a liquid environment. J Surg Res 1992;52(1):50–8
   PubMed Web of Science ®Google Scholar
• Dafer RM, Dafer RM, Schneck M, et al. Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol 2007;22(3):201–4
   PubMedGoogle Scholar
• Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006;90(12):1542–7
   PubMed Web of Science ®Google Scholar
• Gillies MC. What we don't know about avastin might hurt us. Arch Ophthalmol 2006;124(10):1478–9
   PubMedGoogle Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96(12):1788–95
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119(7):1399–411
   PubMed Web of Science ®Google Scholar
• Cunha-Vaz J, Faria de Abreu JR, Campos AJ. Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol 1975;59(11):649–56
   PubMed Web of Science ®Google Scholar
• Davidovic SP, Nikolic SV, Curic NJ, et al. Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy. Eur J Ophthalmol 2012;22(5):792–8
   PubMed Web of Science ®Google Scholar
• El-Mollayess GM, Saadeh JS, Salti HI. Exogenous endophthalmitis in diabetic patients: a systemic review. ISRN Ophthalmol 2012;2012:456209
   PubMedGoogle Scholar
• Chen E, Lin MY, Cox J, et al. Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Retina 2011;31(8):1525–33
   PubMed Web of Science ®Google Scholar
• Abell RG, Kerr NM, Allen P, et al. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol 2012;96(12):1474–8
   PubMed Web of Science ®Google Scholar
• Tabandeh H, Boscia F, Sborgia A, et al. Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting. Retina 2014;34(1):18–23
   PubMed Web of Science ®Google Scholar
• Meyer CH, Mennel S, Eter N. Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application. Ophthalmology 2007;104(11):952–7
   Google Scholar
• Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008;145(5):879–82
   PubMed Web of Science ®Google Scholar
• Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24(5 Suppl):S3–19
   PubMed Web of Science ®Google Scholar
• Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology 1991;98(12):1769–75
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology 2002;109(1):13–24
   PubMed Web of Science ®Google Scholar
• Bhavsar AR, Stockdale CR, Ferris FL 3rd, et al. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol 2012;130(6):809–10
   PubMed Web of Science ®Google Scholar
• Ta CN, Egbert PR, Singh K, et al. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology 2002;109(11):2036–40; discussion 2040–1
   PubMed Web of Science ®Google Scholar
• Isenberg SJ, Apt L, Yoshimori R, et al. Chemical preparation of the eye in ophthalmic surgery. IV. Comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol 1985;103(9):1340–2
   PubMedGoogle Scholar
• Hariprasad SM, Blinder KJ, Shah GK, et al. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous. Arch Ophthalmol 2005;123(1):39–44
   PubMedGoogle Scholar
• Puustjarvi T, Terasvirta M, Nurmenniemi P, et al. Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye. Graefes Arch Clin Exp Ophthalmol 2006;244(12):1633–7
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Sakamoto M, Hata Y, et al. Aqueous and vitreous penetration of levofloxacin after topical and/or oral administration. Eur J Ophthalmol 2007;17(3):372–6
   PubMed Web of Science ®Google Scholar
• Yalvac IS, Basci NE, Bozkurt A, et al. Penetration of topically applied ciprofloxacin and ofloxacin into the aqueous humor and vitreous. J Cataract Refract Surg 2003;29(3):487–91
   PubMed Web of Science ®Google Scholar
• Falavarjani KG, Modarres M, Hashemi M, et al. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinical center. Retina 2013;33(5):971–4
   PubMed Web of Science ®Google Scholar
• Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol 2011;151(2):329–32
   PubMed Web of Science ®Google Scholar
• Milder E, Vander J, Shah C, et al. Changes in antibiotic resistance patterns of conjunctival flora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology 2012;119(7):1420–4
   PubMed Web of Science ®Google Scholar
• Bhavsar AR, Googe JM, Stockdale CR, et al. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol 2009;127(12):1581–3
   PubMedGoogle Scholar
• Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109(5):920–7
   PubMed Web of Science ®Google Scholar
• McCannel CA, Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31(4):654–61
   PubMed Web of Science ®Google Scholar
• Moss JM, Sanislo SR, Ta CN. A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. Ophthalmology 2009;116(8):1498–501
   PubMed Web of Science ®Google Scholar
• Aas JA, Paster BJ, Stokes LN, et al. Defining the normal bacterial flora of the oral cavity. J Clin Microbiol 2005;43(11):5721–32
   PubMed Web of Science ®Google Scholar
• Fagan XJ, Al-Qureshi S. Intravitreal injections: a review of the evidence for best practice: response. Clin Experiment Ophthalmol 2014;42(1):98–100
   PubMed Web of Science ®Google Scholar
• Boden JH, Myers ML, Lee T, et al. Effect of lidocaine gel on povidone-iodine antisepsis and microbial survival. J Cataract Refract Surg 2008;34(10):1773–5
   PubMed Web of Science ®Google Scholar
• Doshi RR, Leng T, Fung AE. Povidone-iodine before lidocaine gel anesthesia achieves surface antisepsis. Ophthalmic Surg Lasers Imaging 2011;42(4):346–9
   PubMed Web of Science ®Google Scholar
• Miller JJ, Scott IU, Flynn HW Jr, et al. Acute-onset endophthalmitis after cataract surgery (2000–2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol 2005;139(6):983–7
   PubMed Web of Science ®Google Scholar
• Inman ZD, Anderson NG. Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia. Retina 2011;31(4):669–72
   PubMed Web of Science ®Google Scholar
• Lad EM, Maltenfort MG, Leng T. Effect of lidocaine gel anesthesia on endophthalmitis rates following intravitreal injection. Ophthalmic Surg Lasers Imaging 2012;43(2):115–20
   PubMedGoogle Scholar
• Blaha GR, Tilton EP, Barouch FC, et al. Randomized trial of anesthetic methods for intravitreal injections. Retina 2011;31(3):535–9
   PubMed Web of Science ®Google Scholar
• Kaderli B, Avci R. Comparison of topical and subconjunctival anesthesia in intravitreal injection administrations. Eur J Ophthalmol 2006;16(5):718–21
   PubMed Web of Science ®Google Scholar
• Cintra LPL, Silva LRDA, Costa JA, et al. Comparative study of analgesic effectiveness using three different anesthetic techniques for intravitreal injection of bevacizumab. Ophthalmic Surg Lasers Imaging 2009;40(1):13–18
   PubMedGoogle Scholar
• Jager RD, Aiello LP, Patel SC, et al. Risks of intravitreous injection: a comprehensive review. Retina 2004;24(5):676–98
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012;119(4):789–801
   PubMed Web of Science ®Google Scholar
• Ladas ID, Karagiannis DA, Rouvas AA, et al. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 2009;29(3):313–18
   PubMed Web of Science ®Google Scholar
• Loukopoulos V, Meier C, Gerding H. Hemorrhagic complications after intravitreal injections of ranibizumab in patients under coumarin-type anticoagulation. Klin Monbl Augenheilkd 2010;227(4):289–91
   PubMed Web of Science ®Google Scholar
• Mason JO, 3rd Frederick PA, Neimkin MG, et al. Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients. Retina 2010;30(9):1386–9
   PubMed Web of Science ®Google Scholar
• Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112(4):593–8
   PubMed Web of Science ®Google Scholar
• Jobling AI, Augusteyn RC. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom 2002;85(2):61–75
   PubMedGoogle Scholar
• James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther 2007;23(5):403–20
   PubMed Web of Science ®Google Scholar
• Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113(9):1533–8
   PubMed Web of Science ®Google Scholar
• Lam DS, Chan CK, Mohammed S, et al. A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema. Br J Ophthalmol 2007;91(2):199–203
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115(9):1447–9
   PubMed Web of Science ®Google Scholar
• Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127(3):245–51
   PubMedGoogle Scholar
• Haller JA, Kuppermann BD, Williams GA, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010;128(3):289–96
   PubMed Web of Science ®Google Scholar
• Rishi P, Rishi E, Kuniyal L, et al. Short-term results of intravitreal dexamethasone implant (OZURDEX(R)) in treatment of recalcitrant diabetic macular edema: a case series. Oman J Ophthalmol 2012;5(2):79–82
   PubMedGoogle Scholar
• Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011;31(5):915–23
   PubMed Web of Science ®Google Scholar
• Thompson JT. Cataract formation and other complications of intravitreal triamcinolone for macular edema. Am J Ophthalmol 2006;141(4):629–37
   PubMed Web of Science ®Google Scholar
• Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol 2004;122(3):336–40
   PubMedGoogle Scholar
• Gillies MC, Kuzniarz M, Craig J, et al. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology 2005;112(1):139–43
   PubMed Web of Science ®Google Scholar
• Cekic O, Chang O, Tseng JJ, et al. Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 2005;139(6):993–8
   PubMed Web of Science ®Google Scholar
• Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol 1998;26(4):277–81
   PubMedGoogle Scholar
• Jones R, 3rd Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006;17(2):163–7
   PubMed Web of Science ®Google Scholar
• Yilmaz T, Weaver CD, Gallagher MJ, et al. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 2009;116(5):902–11; quiz 912–3
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87(1):24–7
   PubMed Web of Science ®Google Scholar
• Scott IU, Flynn HW Jr. Reducing the risk of endophthalmitis following intravitreal injections. Retina 2007;27(1):10–2
   PubMed Web of Science ®Google Scholar
• Moshfeghi DM, Kaiser OK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136(5):791–6
   PubMed Web of Science ®Google Scholar
• Cakir MU, Acar CA, Unver N, et al. Intravitreal triamcinolone acetonide injection for the management of diabetic macular edema. European Vitreoretinal Society; Orebro, Sweden, June 18--22, 2005
   Google Scholar
• Gillies MC, McAllister IL, Zhu M, et al. Pretreatment with intravitreal triamcinolone before laser for diabetic macular edema: 6-month results of a randomized, placebo-controlled trial. Invest Ophthalmol Vis Sci 2010;51(5):2322–8
   PubMed Web of Science ®Google Scholar
• Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 2004;111(11):2044–9
   PubMed Web of Science ®Google Scholar
• Osaadon P, Fagan XJ, Lifshitz T, et al. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye (Lond) 2014;28(5):510--20
   PubMed Web of Science ®Google Scholar
• Yeh PT, Yang CM, Lin YC, et al. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina 2009;29(6):768–74
   PubMed Web of Science ®Google Scholar
• Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92(2):213–16
   PubMed Web of Science ®Google Scholar
• Jalil A, Fenerty C, Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye (Lond) 2007;21(12):1541
   PubMed Web of Science ®Google Scholar
• Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, et al. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One 2008;3(7):e2675
   Web of Science ®Google Scholar
• Arevalo JF, Sanchez JG, Lasave AF, et al. Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture. J Ophthalmol 2011;2011:584238. 13p
   Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol 2013;131(3):283–93
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond) 2009;23(1):181–5
   PubMed Web of Science ®Google Scholar
• Good TJ, Kimura AE, Mandava N, et al. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95(8):1111–14
   PubMed Web of Science ®Google Scholar
• Hoang QV, Mendonca LS, Della Torre KE, et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012;119(2):321–6
   PubMed Web of Science ®Google Scholar
• Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40(3):293–5
   PubMedGoogle Scholar
• Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010;26(1):105–10
   PubMed Web of Science ®Google Scholar
• Kernt M, Welge-Lussen U, Yu A, et al. Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmology 2007;104(11):965–71
   Google Scholar
• Liu L, Wu WC, Yeung L, et al. Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging 2010;41(1):72–7
   PubMedGoogle Scholar
• Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93(4):457–62
   PubMed Web of Science ®Google Scholar
• Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90(11):1344–9
   PubMed Web of Science ®Google Scholar
• Agrawal S, Joshi M, Christoforidis JB. Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflamm 2013;2013:943409
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113(4):623 e1
   PubMed Web of Science ®Google Scholar
• Papadopoulou DN, Mendrinos E, Mangioris G, et al. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116(9):1755–61
   PubMed Web of Science ®Google Scholar
• Michaelides M, Fraser-Bell S, Hamilton R, et al. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina 2010;30(5):781–6
   PubMed Web of Science ®Google Scholar
• Brown DM, Nguyen QD, Marcus DM, et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013;120(10):2013–22
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011;118(4):615–25
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010;33(11):2399–405
   PubMed Web of Science ®Google Scholar
• Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011;118(9):1819–26
   PubMed Web of Science ®Google Scholar
• Do DV, Nguyen QD, Boyer D, et al. One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012;119(8):1658–65
   PubMed Web of Science ®Google Scholar
• Brown DM. Intravitreal Aflibercept Injection (IAI) for Diabetic Macular Edema (DME): primary and additional endpoint results from the 12-month phase 3 VISTA-DME and VIVID-DME studies. ARVO 2014 Annual Meeting; Orlando, FL, 2014
   Google Scholar
• Lorenz K. Evaluation of intravitreal aflibercept for treatment of diabetic macular edema: visual acuity subgroups in VIVID-DME and VISTA-DME. ARVO 2014 Annual Meeting; Orlando, FL, 2014
   Google Scholar
• Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246(1):81–7
   PubMed Web of Science ®Google Scholar
• Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130(8):972–9
   PubMed Web of Science ®Google Scholar
• Goyal S, Lavalley M, Subramanian ML. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2011;249(1):15–27
   PubMed Web of Science ®Google Scholar
• Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114(10):1860–7
   PubMed Web of Science ®Google Scholar
• Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28(10):1395–9
   PubMed Web of Science ®Google Scholar